EP Patent

EP3981763A1 — A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid

Assigned to Sage Therapeutics Inc · Expires 2022-04-13 · 4y expired

What this patent protects

This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Fo…

USPTO Abstract

This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula ( I ) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula ( I ) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3981763A1
Jurisdiction
EP
Classification
—
Expires
2022-04-13
Drug substance claim
No
Drug product claim
No
Assignee
Sage Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.